Recruiting

HOPE-C

Sponsor:

Fred Hutchinson Cancer Center

Code:

NCT07282158

Conditions

Ovarian Carcinoma

Psychiatric Disorder

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

Behavioral Intervention

Interview

Survey Administration

Study Details

Brief summary:

This clinical trial tests an adapted version of the Helping Ovarian Cancer Patients Cope (HOPE) intervention to address burnout among gynecologic oncology clinicians. Stress and burnout among gynecologic oncology clinicians can have far-reaching impacts not only on physicians at the individual level (e.g., distress, mental illness) but also at the professional (e.g., worse patient outcomes, increased errors) and societal levels (fewer physicians in this specialty, more system strain). The original Helping Ovarian Cancer Patients Cope (HOPE) is a workshop to promote hope among patients with ovarian cancer through creating positive narratives using the hope theory and social-cognitive theory. The adapted intervention for clinicals (HOPE-C) will use the same concepts but tailored to clinician experiences by fostering peer support and retelling their challenging stories and may address burnout for gynecologic oncology clinicians.

Conditions

Ovarian Carcinoma

Psychiatric Disorder

Study ID

NCT07282158

Start date

Feb 24, 2026

Status verified date

Jun, 2026

Completion date

Dec 31, 2029

Anticipated

Primary completion date

Dec 31, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Age 18 years of age or older
  • English speaking
  • Able to provide informed consent
  • Working with patients with ovarian cancer (gynecologic oncologists, medical oncologists, nurses, social workers, and advance practice providers \[APPs\])

Study Design

Enrollment

25 participants

Anticipated

Intervention Model

Single group

Primary purpose

Health Services Research

Interventions and Outcome Measures

Arms

experimental: HOPE-C intervention

OBJECTIVE 1 DEVELOPMENT OF INTERVENTION: Clinicians review HOPE-C intervention materials and complete an interview and questionnaire on study. Feedback from Objective 1 will be incorporated into the HOPE-C intervention delivered in Objective 2.

OBJECTIVE 2 PILOT TRIAL: Clinicians attend HOPE-C sessions (changing their narrative, managing life's uncertainty and finding meaning) once weekly for 4 weeks, with each session lasting approximately 30-45 minutes. Clinicians complete a questionnaire before and after completing all HOPE-C sessions.

OBJECTIVE 3: Clinicians may undergo an interview after completing HOPE-C sessions.

Interventions

Behavioral Intervention

Complete HOPE-C sessions

Interview

Complete interview

Survey Administration

Ancillary studies

Primary outcome measure

  • Objective 1: Clinician feedback for Helping Ovarian Cancer Patients Cope-Clinician Burnout (HOPE-C) [ Time Frame: Day 1 ]
  • Objective 2: Feasibility (Accrual rate) [ Time Frame: At time of enrollment ]
  • Objective 2: Feasibility (Rate of intervention completion) [ Time Frame: At 4 weeks ]
  • Objective 2: Feasibility (Rate of survey completion) [ Time Frame: At baseline and 2-week post-intervention ]
  • Objective 2: Acceptability of HOPE-C [ Time Frame: At 2-week post-intervention ]
  • Objective 2: Satisfaction of HOPE-C [ Time Frame: At 2-week post-intervention ]
  • Objective 3: Optimization of the intervention [ Time Frame: At 2-week post-intervention ]
  • Objective 3: Delivery of the intervention [ Time Frame: At 2-week post-intervention ]

Central Contacts and Locations

Central contacts

Megan J. Shen, PhD

206-667-4172mshen2@fredhutch.org

Locations

Fred Hutch/University of Washington Cancer Consortium

Recruiting

Seattle, Washington, United States, 98109

Contacts

Megan J. Shen, PhD

206-667-4172mshen2@fredhutch.org

Principal Investigator:

Megan J. Shen, PhD

More Information

Sponsor

Fred Hutchinson Cancer Center

Last update posted

Jun 17, 2026

Last verified

Jun, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Fred Hutchinson Cancer Center on 2026-06-17.